Showing results (121-130 of 150) with videos related to

Sort By:
Pageof 15
Leukemia|January 22, 1998
Immunophenotypic patterns and cytogenetic anomalies in acute non-lymphoblastic leukemia subtypes: a prospective study of 432 patientsR O Casasnovas, L Campos, F Mugneret, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1997
Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgeryD Caillot, O Casasnovas, A Bernard, et al.
Cell Death and Differentiation|February 2, 2008
Interaction of heat-shock protein 90 beta isoform (HSP90 beta) with cellular inhibitor of apoptosis 1 (c-IAP1) is required for cell differentiationC Didelot, D Lanneau, M Brunet, et al.
Cell Death and Differentiation|November 1, 2014
Interaction of heat-shock protein 90β isoform (HSP90β) with cellular inhibitor of apoptosis 1 (c-IAP1) is required for cell differentiationC Didelot, D Lanneau, M Brunet, et al.
Leukemia|April 16, 2011
Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemiasR Itzykson, O Kosmider, T Cluzeau, et al.
Clinical and Experimental Immunology|October 25, 2007
Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytesS Audia, A Nicolas, D Cathelin, et al.
Leukemia|July 11, 2008
Spontaneous and Fas-induced apoptosis of low-grade MDS erythroid precursors involves the endoplasmic reticulumE Gyan, E Frisan, O Beyne-Rauzy, et al.
Leukemia|February 24, 2001
Phase I study of cinchonine, a multidrug resistance reversing agent, combined with the CHVP regimen in relapsed and refractory lymphoproliferative syndromesE Solary, L Mannone, D Moreau, et al.
Leukemia|April 24, 1999
A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Groupe Français des Myélodysplasies. Group Ouest-Est d'étude des Leucémies aiguës myéloïdesE Wattel, E Solary, X Leleu, et al.
Leukemia|May 22, 2013
JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphomaA Bouchekioua, L Scourzic, O de Wever, et al.
Pageof 15